Companies › Italfarmaco
1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 3; Neurology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Givinostat Hydrochloride Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Polycythemia Vera; Duchenne Muscular Dystrophy; Chronic Myeloproliferative Neoplasms | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06093672 | Givinostat Hydrochloride | Phase 3 | Polycythemia Vera | Oncology | Jul 2026 |
| NCT01761968 | Givinostat Hydrochloride | Phase 2 | Chronic Myeloproliferative Neoplasms | Oncology | Dec 2026 |
| NCT05933057 | Givinostat Hydrochloride | Phase 3 | Duchenne Muscular Dystrophy | Neurology | Feb 2028 |
| NCT06769633 | Givinostat Hydrochloride | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Dec 2029 |
| NCT03373968 | Givinostat Hydrochloride | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Dec 2029 |
Great Novel Therapeutics Biotech & Medicals Acrotech Biopharma Xynomic Pharmaceuticals AB Science SK Life Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.